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Clostridium difficile is a Gram-positive, spore-forming anaerobic human gastrointestinal
pathogen. C. difficile infection (CDI) is a major health concern worldwide, with symptoms
ranging from diarrhea to pseudomembranous colitis, toxic megacolon, sepsis, and
death. CDI onset and progression are mostly caused by intestinal dysbiosis and
exposure to C. difficile spores. Current treatment strategies include antibiotics; however,
antibiotic use is often associated with high recurrence rates and an increased risk of
antibiotic resistance. Medium-chain fatty acids (MCFAs) have been revealed to inhibit
the growth of multiple human bacterial pathogens. Components of coconut oil, which
include lauric acid, have been revealed to inhibit C. difficile growth in vitro. In this
study, we demonstrated that lauric acid exhibits potent antimicrobial activities against
multiple toxigenic C. difficile isolates in vitro. The inhibitory effect of lauric acid is partly
due to reactive oxygen species (ROS) generation and cell membrane damage. The
administration of lauric acid considerably reduced biofilm formation and preformed
biofilms in a dose-dependent manner. Importantly, in a mouse infection model, lauric
acid pretreatment reduced CDI symptoms and proinflammatory cytokine production.
Our combined results suggest that the naturally occurring MCFA lauric acid is a novel
C. difficile inhibitor and is useful in the development of an alternative or adjunctive
treatment for CDI.
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INTRODUCTION
Clostridium difficile is a Gram-positive, spore-forming bacillus that was first isolated from the gut of
an infant and became medically important when it was found to be the leading cause of antibiotic-
associated diarrhea (AAD) in hospital settings worldwide (Smits et al., 2016). It is estimated that
15–25% of AAD cases can be attributed to C. difficile infection (CDI) (Ananthakrishnan, 2011).
Partly due to increased awareness and diagnosis, the incidence and economic burden of CDI
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have increased yearly, and CDI cases have been reported in every
continent (Burke and Lamont, 2014; Desai et al., 2016). Prior
antibiotic exposure, advanced age (more than 65 years), prior
hospitalization, the presence of an underlying illness, and proton
pump inhibitor use have all been identified as risk factors for CDI
(Vardakas et al., 2012; McDonald et al., 2015).
The principal virulence factors of C. difficile are two large
cytotoxins, toxin A and toxin B, which have been reported
to exhibit enterotoxigenic and cytotoxic activity (Pruitt et al.,
2010; Abt et al., 2016). Both toxins are capable of severely
inflaming the colon and disrupting the epithelial mucosal surface.
According to the current guideline for CDI treatment, prior
antibiotic retreatment should be discontinued and replaced
with metronidazole as first-line treatment; vancomycin is
administered for extremely severe cases or relapses (Surawicz
et al., 2013). Recurrence, one of the hallmarks of CDI, is due
to the ability of C. difficile to produce stress-resistant spores
and partly due to the inability of the gut flora to be restored
after antibiotic treatment; recurrence can occur in 25% of
patients with CDI, and the rate can increase up to 40–60%
following a second recurrence (Johnson, 2009). The recently
Food and Drug Administration (FDA)-approved antibiotic
fidaxomycin has been identified as having similar treatment
effects as those of vancomycin while having a reduced impact
on the gut flora (Louie et al., 2012), although the recurrence
rate is still high. Several vaccines developed by pharmaceutical
companies are currently being tested in clinical trials, but no
active immunization therapies have been approved by the FDA.
However, bezlotoxumab, an antitoxin B monoclonal antibody,
has been approved for preventing CDI recurrence (Martin and
Wilcox, 2016; Villafuerte Galvez and Kelly, 2017). Alternative
treatment and preventive strategies against CDI are therefore
required.
Various free fatty acids (FAs), as well as their monoglyceride
derivatives, have long been known to exert antimicrobial
effects on numerous bacterial pathogens (Galbraith et al.,
1971; Kabara et al., 1972). Short-chain fatty acids (SCFAs)
such as acetic, propionic, and butyric acid have been proven
to exhibit antibacterial activity against various pathogens
including Vibrio parahaemolyticus, C. perfringens, Salmonella,
and Helicobacter pylori (Thompson and Hinton, 1997; Namkung
et al., 2011; Immanuel et al., 2012; Yonezawa et al., 2012). Of
all medium-chain fatty acids (MCFAs) tested in vitro, lauric acid
(dodecanoic acid, C12:O) and capric acid (decanoic acid, C10:O)
have been demonstrated to have the most potent effect against
various bacterial, fungal, and viral pathogens (Kabara et al., 1972;
Bartolotta et al., 2001; Bergsson et al., 2001; Rouse et al., 2005;
Huang et al., 2011). Lauric acid, in particular, has been revealed
to exhibit antibacterial activity against both Gram-positive
and Gram-negative pathogens such as Staphylococcus aureus,
Streptococcus mutans, S. pyogenes, Escherichia coli, H. pylori, and
many others (Kabara et al., 1972; Rouse et al., 2005). A recent
study demonstrated the bactericidal effects of MCFAs (caprylic,
capric, and lauric acid) combined with edible plant essential
oils (carvacrol, eugenol, β-resorcylic acid, trans-cinnamaldehyde,
thymol, and vanillin) against E. coli O157:H7 (Kim and Rhee,
2016). As the primary FA of coconut oil is lauric acid (45–53%), it
is of great interest to utilize coconut oil as a source of lauric acid.
The antimicrobial properties of lauric acid, monolaurin, and their
ester derivatives may be attributed to physicochemical processes
as well as their interference with various cellular processes
(Dayrit, 2015). Shilling et al. (2013) reported that MCFAs can
inhibit the growth of the C. difficile strain ATCC 9689 in vitro, and
that lauric acid exhibits the highest potency. However, the extent
of and the mechanism by which lauric acid inhibits C. difficile
and its destructive effects on bacterial physiology and the spore
outgrowth ability have not been investigated comprehensively,
and importantly, the effect of lauric acid on CDI in vivo has not
been analyzed.
In the present study, we screened multiple FAs for their
ability to inhibit C. difficile growth in vitro and confirmed that
lauric acid exerts the highest inhibitory effect. A comprehensive
analysis demonstrated that lauric acid could inhibit biofilm
formation and reduce spore outgrowth. Mechanistic studies
revealed that the inhibition of C. difficile was partly due to the
generation of intracellular reactive oxygen species (ROS) and
membrane damage. In a mouse infection model, lauric acid
consumption decreased CDI-induced colon inflammation and
diarrhea, supporting the hypothesis that lauric acid is a potential
compound for CDI treatment.
MATERIALS AND METHODS
C. difficile Strains and Culturing
Conditions
Eleven C. difficile strains were utilized in this study. Strains
R20291 (ribotype 027, tcdA+, tcdB+, tcdC+, cdtA−, ctdB+)
and 630 (ribotypes 012, tcdA+, tcdB+, tcdC+, ctdA−, ctdB−)
used in this study are described elsewhere (McEllistrem et al.,
2005; Buckley et al., 2011). The other nine isolates, which
consisted of three tcdA+tcdB+ isolates (TNHP 29, 59, and
207), three tcdA−tcdB+ isolates (TNHP 79, 82, 403), and three
tcdA−tcdB− isolates (1, 3, and 6), were originally isolated from
a hospital in Southern Taiwan and have been described by Hung
et al. (2016). All C. difficile strains were cultured anaerobically on
brain–heart infusion (BHI) agar or in BHI broth (Thermo Fisher
Scientific, Waltham, MA, United States) supplemented with
0.05% L-cysteine. Anaerobic experiments were conducted inside
a Don Whitley DG250 anaerobic workstation (Don Whitley
Scientific Ltd., West Yorkshire, United Kingdom).
Fatty Acid Minimum Inhibitory
Concentration (MIC), Minimum
Bactericidal Concentration (MBC), and
Half Maximal Inhibitory Concentration
(IC50) Determination
Fatty acids (propionic acid, butyric acid, isobutyric acid, valeric
acid, isovaleric acid, hexanoic acid, octanoic acid, capric acid,
lauric acid, myristic acid, and palmitic acid) were purchased
from Sigma–Aldrich (St. Louis, MO, United States). A minimum
inhibitory concentration (MIC) assay was conducted according
to the guidelines of the Clinical Laboratory and Standards
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Institute (formerly the National Committee for Clinical
Laboratory Standards) for anaerobes. An overnight-grown
culture was refreshed 50-fold in fresh brain–heart infusion-
supplemented (BHIS) broth, incubated until the optical density
at 600 nm (OD600) was approximately 0.35, and then diluted
8-fold in 96-well microplates. FAs predissolved in dimethyl
sulfoxide (DMSO) were then added to the bacterial suspension
to reach a 5% DMSO final concentration. Concentrations of
FAs ranged from 0.01 to 5 mg/mL. Bacterial cells were also
incubated in BHIS + 1% DMSO only as a control. Plates were
incubated anaerobically at 37◦C for 24 h. To determine the
MBC, bacterial suspensions from each well were streaked out
onto BHIS agar plates and incubated for an additional 24 h.
The MBC of each FA was defined as the lowest concentration
at which no visible colony was observed. To determine the
inhibitory effects of different concentrations of lauric acid on
the C. difficile strain R20291, the percentage of growth at each
concentration was calculated using the following equation:
inhibition (%) = [1 − (OD600 of growth with lauric acid/OD600
of growth in broth only) × 100]. The growth inhibition rate was
plotted against the log of the lauric acid concentration, and the
IC50 value was defined as the value that caused a 50% reduction
in bacterial growth. At least three independent samples were
analyzed for each experiment.
Growth Curves of Various
Concentrations of Lauric Acid Incubated
with C. difficile
To determine the antibacterial activity of lauric acid on C. difficile
growth, we employed different concentrations of lauric acid
(1×, 4×, and 8× MBC) in the growth assay conducted
in an anaerobic chamber. In the assay, 1% DMSO served
as a treatment control. The C. difficile strain R20291 was
cultured in BHIS broth at 37◦C in the anaerobic chamber
for 16 h, and the overnight cultures were then refreshed 50-
fold in fresh BHIS broth until the late exponential to early
stationary phase (OD600 = approximately 0.8). Next, bacterial
suspensions were added to DMSO or lauric acid, and OD595 was
determined using a Libra S2 Colorimeter (Biochrom, Cambridge,
United Kingdom). At least three independent samples were
analyzed for each experiment.
Biofilm Assay
To determine the effect of lauric acid on biofilm formation,
an overnight culture of the C. difficile strain R20291 was
refreshed to the late exponential to early stationary phase
(OD600 = approximately 0.8) in BHIS broth and then diluted
100-fold in fresh medium (BHIS + 0.1 M glucose) in 24-well
polystyrene plates. Lauric acid at concentrations ranging from
0.125× to 1× MBC was added, and plates were incubated
anaerobically at 37◦C for 72 h. To determine the effect of
lauric acid on preformed biofilms, biofilms were prepared for
24 h before treatment with lauric acid at concentrations ranging
from 1× to 4× MBC for another 24 h. Moreover, 20 µg/mL
vancomycin [40× the MBC of strain R20291, (Dapa et al., 2013)]
and 1% DMSO were used as controls. To quantify the biofilm
mass, supernatants were carefully decanted, and biofilms that
formed in all wells were allowed to dry at room temperature.
Two percent crystal violet (CV) was added to each well for
30 min and then removed through methanol treatment for an
additional 30 min. Extracted dye contents were quantified by
measuring the absorbance at 595 nm by using a MultiskanTM
GO Microplate Spectrophotometer (Thermo Fisher Scientific).
Experiments were performed at least three times.
Spore Preparation
Spores were prepared by plating a 1:100 dilution of overnight
culture onto BHIS agar plates and then incubating the plates
for 10 days at 37◦C under anaerobic conditions. Spores were
harvested with ice-cold sterile distilled water and purified
with 50% Nicodenz (Axis Shield, Oslo, Norway) using a
previously described method (Sorg and Sonenshein, 2008).
Spores were purified to >99% purity as determined using phase
contrast microscopy, and the number of spores per milliliter
was quantified through visual enumeration using a Neubauer
Chamber (Sigma–Aldrich) prior to use.
Spore Germination and Outgrowth Assay
To monitor germination efficiency, purified spores were first heat
activated by incubating them for 30 min at 60◦C and were then
adjusted to an OD600 of 1.0 in sterile water; 75-µL aliquots of
spore suspensions were mixed with equal volumes of lauric acid
or sterile water supplemented with 5% DMSO for 20 min at room
temperature. Next, 10 mM taurocholic acid (Fisher Scientific) was
added, and OD600 was measured at 2-min intervals (MultiskanTM
GO Microplate Spectrophotometer, Thermo Fisher Scientific).
The ratio of the OD600 at time X to the OD600 at time zero (t0) was
plotted against time. The level of dipicolinic acid (DPA) release
was monitored in real-time through terbium fluorescence, as
described in previous studies (Bhattacharjee et al., 2015; Francis
et al., 2015). Briefly, 75 µL of purified spores previously adjusted
to the OD600 of 1.0 were resuspended in germination buffer
(10 mM Tris-Cl, 150 mM NaCl, 100 mM glycine, pH 7.5) and
were then treated with equal volumes of various concentrations
of lauric acid for 20 min. Next, 10 mM taurocholic acid was
added, and DPA release was monitored using a FlexStation R© 3
Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale,
CA, United States) at an excitation wavelength of 270 nm
and an emission wavelength of 545 nm. Spores boiled at
100◦C for 30 min served as a positive control for total DPA
release. Statistical analysis was performed using GraphPad Prism
version 6.0. Three independent experiments were conducted.
DPA release was calculated using the following equation:
DPA release (%) = RFUsample
Average of RFUboiled spores
× 100%
To measure spore outgrowth, from the aforementioned
germination assay, a 100-µL aliquot of spores from each reaction
was serially diluted (10−1–10−7) with sterile phosphate-buffered
saline (PBS) and then spread onto BHIS agar plates supplemented
with 0.l% sodium taurocholate (TA) and incubated anaerobically
at 37◦C overnight. Spore outgrowth was calculated using the
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following equation:
Spore outgrowth (%)
= CFU countlauric acid treated sample
Average of CFU countDMSO control
× 100%
Cytoplasmic Material Leakage
Measurement
An overnight culture of C. difficile R20291 was diluted at 1:50 in
fresh BHIS broth and then grown to an OD600 of approximately
0.8. Bacterial cells were then treated with various concentrations
of lauric acid (1×–8× MBC) anaerobically at 37◦C. Moreover,
1% DMSO in PBS served as the negative control, and 100 µg/mL
nisin (Sigma–Aldrich) served as the positive control. At various
time points, supernatants were collected, and the absorbances
at 260 nm were recorded using a BioPhotometer UV/Visible
Spectrophotometer (Eppendorf, Hamburger, Germany). Three
independent experiments were performed.
Live/Dead Bacterial Viability
Measurement
To measure cell viability, an overnight culture of C. difficile
R20291 was diluted at 1:50 in fresh BHIS broth and then
grown to an OD600 of approximately 0.8. Bacterial cells were
then treated with lauric acid at 0.25× MBC or 1% DMSO
in PBS for 20 min. Bacterial pellets were collected and
resuspended in sterile PBS. Suspensions were then mixed with
the LIVE/DEAD BacLight staining reagent mixture (Molecular
Probes, Invitrogen) according to the manufacturer’s instructions.
Samples were visualized under a FluoViewTM FV1000 confocal
microscope (Olympus), and fluorescence was detected at an
excitation wavelength of 488 nm and an emission wavelength of
500 nm (SYTO9) and 635 nm (propidium iodide). Cell viability is
expressed as the ratio of SYTO-9-stained cells to the total number
of cells. At least three independent trials were performed for each
experiment.
Ultrathin-Section Transmission Electron
Microscopy
Transmission electron microscopy (TEM) was employed to
visualize the cells damaged by lauric acid treatment. C. difficile
R20291 cells grown to the exponential phase were concentrated
through centrifugation and treated with 0.25× MBC of lauric
acid anaerobically for 15 min. Samples were embedded in
Embed-812 (Electron Microscopy Sciences) and cut with an EM
UC6 ultramicrotome (Leica, Wetzlar, Germany). Sections with
a thickness of 90 nm were placed on copper grids (Electron
Microscopy Sciences) and then stained with 2% uranyl acetate
and lead citrate. Ultrathin sections were examined under a JEM-
1400 transmission electron microscope (JEOL) with 120 kV
acceleration and a 4k × 4k CCD Camera System Model 895
(Gatan, Inc.). The results are representative of three independent
experiments.
Fluorescent Dye-Based Detection of
ROS
Reactive oxygen species was measured using the carboxy
derivative of fluorescein, CM-H2DCFDA (Life Technologies),
according to the protocol provided by the manufacturer with the
following modification: briefly, an overnight-grown C. difficile
culture was refreshed to OD600 of approximately 0.8 in BHIS
broth. Moreover, 198 µL of the bacterial suspension was
incubated with 2 µL of stock CM-H2DCFDA anaerobically at
37◦C for 30 min. Cells were then treated with 1× MBC of
lauric acid for 10 min, and fluorescence was then measured using
the FlexStation R© 3 Multi-Mode Microplate Reader (Molecular
Devices) at an excitation wavelength of 488 nm and an
emission wavelength of 535 nm. The following controls were
included: bacterial suspensions in BHIS broth containing 1%
DMSO as the negative control; bacterial suspensions in BHIS
broth containing 0.0035% hydrogen peroxide solution (H2O2;
Sigma–Aldrich) and 10 mM tert-butyl hydroperoxide solution
(TBHP; Sigma–Aldrich) as the positive control. The results are
representative of three independent experiments.
Bacterial RNA Extraction and Real-Time
Quantitative Reverse Transcription
Polymerase Chain Reaction
An overnight culture of C. difficile R20291 was refreshed in
Tryptone Yeast or BHIS broth and was grown anaerobically at
37◦C until OD600 was approximately 0.8. Bacterial cells were
treated with various concentrations of lauric acid or 1% DMSO
(control group) for 30 min anaerobically at 37◦C. Cells were
harvested through centrifugation, and total RNA was isolated
using the RNAprotect Bacteria Reagent (QIAGEN, Venlo,
Netherlands) in accordance with the manufacturer’s instructions.
Genomic DNA was removed using RQ1 RNase-free DNase
(Promega). RNA was reverse transcribed into complementary
DNA (cDNA) by using SuperScriptTM II Reverse Transcriptase
(Invitrogen) and random primers (Thermo Fisher Scientific)
according to the manufacturer’s instructions. The relative
transcriptional level of putative ROS-related genes between
the control group and the lauric acid treatment group was
measured through real-time quantitative reverse transcription
polymerase chain reaction (qRT-PCR) using the 2x qPCRBIO
SyGreen Mix Hi-Rox (PCR Biosystems) and gene specific
primers (Table 1), according to the manufacturer’s instructions.
A StepOnePlusTM Real-Time PCR System (Applied Biosystems)
was used. The data were analyzed using the 2−11Ct method,
with normalization to the reference gene 16s and the stated
reference condition. Samples were analyzed in at least three
independent trials. Statistical analyses were performed using
GraphPad Prism 6.0.
An Animal Model of CDI
Specific-pathogen-free 8-week-old male C57BL/6 mice were
housed in the Laboratory Animal Center of (NCKU). All mice
were maintained and handled according to the guidelines of
the Institutional Animal Care and Use Committee (IACUC) of
NCKU. All animal studies were performed following the protocol
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approved by the IACUC of NCKU (approval NCKU-IACUC-
102-149) and the Biosafety and Radiation Safety Management
Division of NCKU. The animal model of CDI was established
as previously described (Chen et al., 2008; Liu et al., 2017;
Pizarro-Guajardo et al., 2017). Five animals were administered
12 mg/kg (low dose) and 24 mg/kg (high dose) of lauric
acid dissolved in PBS orogastrically once per day for 7 days
prior to infection with C. difficile and once more 1 day
following infection. To condition the animals for CDI, mice
were fed drinking water containing an antibiotic mixture, which
included 0.4 mg/mL vancomycin, 0.215 mg/mL metronidazole,
0.4 mg/mL kanamycin, 0.035 mg/mL gentamicin, and 850
U/mL colistin, for a total of 5 days before the challenge. All
antibiotics were purchased from Sigma–Aldrich. On the day
before the challenge, mice were fed the antibiotic mixture without
vancomycin and metronidazole, which were excluded to avoid
disrupting C. difficile colonization. Esomeprazole dissolved in
PBS was given to all mice through oral gavage 12 h prior
to infection (18.55 mg/kg) and immediately before infection
(4.82 mg/kg). On the day of infection, 1 × 106 CFU of C. difficile
R20291 spores were administered through oral gavage, and
4 mg/kg of clindamycin was injected intraperitoneally. Two
days after infection, all animals were euthanized through CO2
asphyxiation. The severity of diarrhea was scored in accordance
with mice stool consistency, as follows: (0) well-formed pellets;
(1) semiformed stools that did not adhere to the anus; (2)
semiformed stools that adhered to the anus; and (3) liquid
stools. Organs and gastrointestinal lavage (GAL) fluids were
extracted for downstream analysis. The entire animal experiment
was performed for a total of three independent sets, and
representative results were obtained.
Fecal Colony-Forming Unit
Determination
Fecal samples (premixed in PBS) were collected from the animals,
immediately heat treated at 65◦C for 20 min, and then serially
diluted onto BHI agar containing 0.1% TA. Plates were incubated
anaerobically at 37◦C for 48 h, and colonies were counted for
CFU determination.
Mice Colon RNA Extraction and
Real-Time Quantitative Reverse
Transcription Polymerase Chain
Reaction
Colon samples were extracted using RNeasy R© Plus Mini kits
(QIAGEN). RNA yield and quality were examined using
a NanoDrop Spectrophotometer (Thermo Fisher Scientific).
Reverse transcription was performed with SuperScriptTM II
Reverse Transcriptase (Invitrogen, Waltham, MA, United States).
The expression levels of proinflammatory cytokines and
chemokines were measured through qRT-PCR using RealQ
TABLE 1 | Sequences of oligonucleotide primers used in this study.
Name Sequence (5′–3′) Species Reference
16s-F GAT TTA CTT CGG TAA AGA GCG G C. difficile This study
16s-R CCT TAC CAA CTA GCT AAT CAG ACG C. difficile This study
TcdA-F AAA GCT TTC GCT TTA GGC AGT G C. difficile This study
TcdA-R CTC TAT GGC TGG GTT AAG GTG TTG C. difficile This study
TcdB-F GAT CAC TTC TTT TCA GCA CCA TCA C. difficile This study
TcdB-R AGC TTC TTA AAC CTG GTG TCC ATC C. difficile This study
CD1529-F TGT CTT TGG TTC TGG TTG GG C. difficile This study
CD1529-R ACT TAC AGG GCT ATC CTG ATT TG C. difficile This study
CD0757-F GAC TTG TGG AAA CCT TGT AGG A C. difficile This study
CD0757-R TGC TGC ATC TGT TGT ATT AGG A C. difficile This study
CD1716-F CTG ACC CTG ACT TAG TTG CTA TAA A C. difficile This study
CD1716-R ATA TGT CGC ACG TAC AAC TCC C. difficile This study
CD1465-F GCT ATG CAA TAC TTG TCC CAA AG C. difficile This study
CD1465-R GCT AAG CTC TTC TGC TGC TAT C. difficile This study
mβ-actin-F ACT GCC GCA TCC TCC TCC TC Mouse Hung et al., 2015
mβ-actin-R TGC CAC AGG ATT CCA TAC CC Mouse Hung et al., 2015
mTNF-α-F CAT CTT CTC AAA ATT CGA GTG ACA A Mouse Hung et al., 2015
mTNF-α-R TGG GAG TAG ACA AGG TAC AAC CC Mouse Hung et al., 2015
mIL-6-F AGG ATA CCA CTC CCA ACA GAC Mouse Hung et al., 2015
mIL-6-R GTG CAT CAT CGT TGT TCA TAC Mouse Hung et al., 2015
mIL-1β-F GCA ACT GTT CCT GAA CTC AAC T Mouse Hung et al., 2015
mIL-1β-R ATC TTT TGG GGT CCG TCA AT Mouse Hung et al., 2015
mMIP-2-F TGT CAA TGC CTG AAG ACC CTG CC Mouse Hung et al., 2015
mMIP-2-R AAC TTT TTG ACC GCC CTT GAG AGT GG Mouse Hung et al., 2015
mMCP-1-F CCC ACT CAC CTG CTG CTA CT Mouse Hung et al., 2015
mMCP-1-R TCT GGA CCC ATT CCT TCT TG Mouse Hung et al., 2015
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Plus 2X Master Mix Green (Ampliqon, Denmark), with
β-actin as the reference gene in each reaction (Table 1). The
data were analyzed using the 11Ct method and expressed
as the fold change in the transcription level under the
test condition compared with the average for the indicated
control and were then normalized to the reference gene
β-actin. Statistical analyses were performed using GraphPad
Prism 6.0.
Cytokine and Chemokine Measurement
The concentrations of GAL cytokines and chemokines were
measured using a DuoSet R© enzyme-linked immunosorbent assay
(ELISA) development system (R&D Systems, Minneapolis, MN,
United States) according to the manufacturer’s instructions.
Absorbance was measured at 450 nm using an iMarkTM
microplate reader (Bio-Rad, Hercules, CA, United States).
Samples were measured in triplicate, and statistical analyses were
performed using GraphPad Prism version 6.0.
Statistics
All data are expressed as the mean ± standard deviations of
at least three independent experiments. Statistical comparisons
among the groups were made using Student’s t-test. Multiple
intergroup comparisons were made using one-way analysis of
variance (ANOVA), followed by a post hoc Tukey’s test with
GraphPad Prism version 6.0. Statistical significance was set at
P < 0.05.
RESULTS
Antibacterial Activity of Free FAs against
C. difficile R20291
To identify the free FAs with potent C. difficile inhibitory
effects, FAs C3–C16 were coincubated with log-phase-grown
C. difficile cells, and their MBCs were determined (Table 2).
For the test strain R20291, butyric acid (MBC = 50 mg/mL)
showed the least inhibitory effects of all FAs tested, whereas
lauric acid (MBC = 0.3125 mg/mL) showed the most potent
effects. The length of the carbon chain did not appear to be
an influencing factor contributing to the antibacterial activity
of the FAs, although remarkably MCFAs appeared to exhibit
lower MBCs. Specifically, the MBCs of both capric acid
(C10) (1.25 mg/mL) and lauric acid (C12) (0.3125 mg/mL)
were the second lowest and the lowest of all FAs tested.
Moreover, the resulting pH variation in BHIS medium did not
appear to contribute to the antibacterial activity of the various
FAs (Table 2). As the MBC of lauric acid was significantly
lower (fourfold, P < 0.0001) than that of capric acid, lauric
acid was chosen as a potential candidate for subsequent
experiments.
To further confirm the inhibitory effect of lauric acid on
C. difficile growth, 10 additional clinical isolates of different
toxinotypes were subjected to the same experiment (Table 3
and Figure 1) (Hung et al., 2016). The MICs of all 11 tested
isolates ranged from 0.08 to 0.16 mg/mL; however, the MBCs
were all 0.31 mg/mL. As the MBCs were all the same, we
assumed the inhibitory effect of lauric acid on C. difficile is
likely not strain-dependent; hence, all subsequent experiments
were performed using the laboratory strains 630 and R20291. To
gain further insight into the inhibitory effect of lauric acid on
C. difficile, the IC50 was determined. As depicted in Figures 2A,B,
the IC50 of lauric acid against C. difficile strains R20291 and
630 was 12.48 and 33.67 µg/mL, respectively. The antibacterial
activity of lauric acid against strain R20291 was further evaluated
in liquid nutrient broth containing different concentrations of
lauric acid (Figure 2C). When lauric acid was applied at 2× and
4× MBC, cell lysis appeared to occur immediately, as evidenced
by the drop in OD. In short, lauric acid was revealed to display
an inhibitory effect on multiple strains of C. difficile, and the
inhibition mechanism is likely bactericidal.
Effects of Lauric Acid Treatment on
Biofilm Formation and Stability
To further understand the effect of lauric acid on C. difficile,
we determined whether lauric acid treatment affects biofilm
formation and stability. In this study, we measured the effect of
lauric acid treatment on biofilm formation by R20291 and 630
strains, as these two strains were reported to exhibit different
biofilm forming abilities (Dapa et al., 2013). Clinical C. difficile
strains are known to form robust biofilms in vitro, and these
biofilm-dwelling cells are more resistant to antibiotics and
perhaps to even host defenses than planktonic cells are (Dapa
and Unnikrishnan, 2013; Dapa et al., 2013; Crowther et al.,
2014). A previous study reported that vancomycin applied at
20 µg/mL (100× MIC) can significantly reduce the survival
of C. difficile biofilm cells (Dapa and Unnikrishnan, 2013).
For the strain R20291, vancomycin applied at 100× MIC
could reduce biofilm formation by 15.5-fold compared with
the DMSO control (P < 0.0001). However, 0.25× MBC of
lauric acid could significantly reduce biofilm formation by 24.9-
fold compared with the control (P < 0.0001) (Figure 3A).
Similarly, for the strain 630, although vancomycin treatment
led to a 20.8-fold reduction in biofilm formation, 0.25×
MBC of lauric acid led to a 47.2-fold reduction (Figure 3B).
To determine whether lauric acid treatment also disrupts
established biofilms, a static culture of C. difficile was grown
in multi-well plates for 24 h before lauric acid addition.
Interestingly, although vancomycin applied at 100× MIC did
not reduce the biofilm mass, lauric acid at least 2× MBC
and 1× MBC could reduce the mass of biofilms formed
by strains R20291 and 630, respectively (Figures 3C,D).
Reduction of the mass of biofilms formed by the strain R20291
required a higher concentration of lauric acid than that from
strain 630.
Effect of Lauric Acid Treatment on Spore
Germination and Outgrowth
In addition to biofilm formation, the spore-forming ability of
C. difficile contributes to its transmission (Deakin et al., 2012).
Spores are known to be resistant to multiple environmental
stresses, including cold, heat, desiccation, antiseptics, and
antibacterial products (Rodriguez-Palacios and Lejeune, 2011;
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TABLE 2 | Antibacterial activity of fatty acids against C. difficile strain R20291.
Number of carbon backbone General name MIC (mg/ml) MBC (mg/ml) pH (in BHIS)
SCFAs C3 Propionic acid 1.25 5 3.91
C4 Butyric acid 25 50 7.11
C4 Isobutyric acid 1.25 5 4.97
C5 Valeric acid 1.25 2.5 5.78
C5 Isovaleric acid 2.5 2.5 5.76
MCFAs C6 Hexanoic acid 1.25 2.5 5.94
C8 Octanoic acid 2.5 5 5.51
C10 Capric acid 0.63 1.25 6.81
C12 Lauric acid 0.31 0.31 6.91
LCFAs C14 Myristic acid >10 >10 6.51
C16 Palmitic acid 10 10 6.77
Clostridium difficile strain R20291 was exposed to various dilutions of different fatty acids for 24 h, and MBC was determined as the concentration of fatty acids at which
no visible growth was observed. Results are expressed as average of at least three independent replicates. SCFA, short-chain fatty acids; MCFA, medium-chain fatty
acids; LCFA, long-chain fatty acids.
TABLE 3 | Inhibition of C. difficile strains by lauric acid.
C. difficile strain Toxin genotype MIC (mg/ml) MBC (mg/ml) Ribotype
R20291 tcdA+tcdB+ (laboratory strains) 0.08 0.31 RT 027
630 0.08 0.31 RT 012
TNHP 20 tcdA+tcdB+ (clinical isolate strains) 0.16 0.31 RT 002
TNHP 59 0.08 0.31 RT 002
TNHP 207 0.16 0.31 RT 106
TNHP 79 tcdA-tcdB+ (clinical isolate strains) 0.08 0.31 RT 017
TNHP 82 0.08 0.31 RT 017
TNHP 403 0.16 0.31 RT 017
TNHP 1 tcdA−tcdB− (isolated from asymptomatic adults ) 0.08 0.31 ND
TNHP 3 0.16 0.31 ND
TNHP 6 0.16 0.31 ND
Clostridium difficile isolates containing two laboratory strains and nine local isolates were exposed to various concentration of lauric acid for 24 h. MBC was determined
as described previously. Results are expressed as average of at least three independent replicates. ND – not determined.
Deng et al., 2015; Edwards et al., 2016), and they are therefore
a critical component of the pathogenesis of CID. One of the
key germinating signals for C. difficile spores is the presence of
TA. In the presence of TA, spores will undergo core hydration,
and this process can be visualized microscopically; previously
dormant phase-dark spores will become phase-bright due to
core hydration and the eventual degradation of the cortex
peptidoglycan. To measure the effect of lauric acid on spore
germination, purified C. difficile strain R20291 spores were
treated with taurocholic acid and various concentrations of lauric
acid. As revealed in Figure 4A, in the presence of TA, the
OD600 of the spore suspension decreased significantly within
20 min of exposure (PC group, P < 0.0001), whereas the
DMSO control remained phase-dark (NC group). Interestingly,
when various concentrations of lauric acid were added along
with TA, the decrease in OD600 was faster over time than that
in the PC group, suggesting that core degradation occurred
at a faster rate (P < 0.0001 for all concentrations compared
with the PC group). We also performed the same assay in
the absence of TA, and no significant decrease in OD600 was
observed for all concentrations of lauric acid tested throughout
the 20 min of observation, suggesting that the effect was
TA-dependent (Figure 4B). During spore germination, DPA
release can be measured and is often used as a sign of spore
germination. To further investigate the role of lauric acid in
spore germination, we measured DPA released for 20 min
(Figure 4C). As expected, DPA released from boiled spores was
detected by its high fluorescence signals, which were higher than
those of non-treated spores. Similarly, in the presence of TA,
an increase in the fluorescent signal was detected, suggesting
that DPA release was initiated at approximately 4 min and
continued to increase until the end of the experiment. However,
the addition of lauric acid, regardless of concentration, did not
significantly alter DPA release over the course of the experiment
(P > 0.9999). Furthermore, the addition of lauric acid alone
did not induce any DPA release (data not shown). Finally, the
viability of spores in the presence of lauric acid was measured
(Figure 4D). Compared with spores exposed to TA only, lauric
acid treatment in the presence of TA considerably decreased
the rate of spore outgrowth in a dose-dependent manner.
Spore outgrowth decreased to 64.5, 61, 60.4, and 39.6% of
typical growth when subjected to lauric acid concentrations of
0.5× MBC, 1× MBC, 2× MBC, and 4× MBC, respectively
(Figure 4D). These combined results demonstrate that lauric acid
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FIGURE 1 | Lauric acid is a potent inhibitor of multiple Clostridium difficile clinical isolates. Growth inhibition of multiple C. difficile isolates on BHI agar plates
containing lauric acid at 0.5× (0.1563 mg/mL), 1× (0.3125 mg/mL), and 2× (0.625 mg/mL) MBC. a: TNHP 207; b: TNHP 59; c: TNHP 20; d: 630; e: R20291; f:
TNHP 403; g: TNHP 82; h: TNHP 79; i: TNHP1; j: TNHP 3; k: TNHP 6; x: negative control. Results are representative of at least three independent experiments.
FIGURE 2 | IC50 determination and time-dependent antibacterial kinetic curve of lauric acid against C. difficile. (A) C. difficile strains R20291 and 630 were treated
with various concentrations of lauric acid for 24 h, and the OD at 600 nm was then measured. Growth inhibition was normalized to the 5% DMSO control group.
(B) Log-phase grown C. difficile R20291 cells were incubated with various concentrations of lauric acid in BHI broth for up to 6 h. (C) C. difficile R20291 cells were
incubated with 1×, 2×, and 4× MBC of lauric acid, and growth was monitored over time by measuring OD595. DMSO was included as a control. Results are
expressed as mean of triplicate samples at least three independent experiments.
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FIGURE 3 | Inhibition of C. difficile biofilm by lauric acid. Various concentrations of lauric acid were added to strains R20291 (A) and 630 (B) grown in multi-well
plates, and adherent biofilms were quantified by CV staining. The effect of lauric acid on preformed biofilms was measured by incubating various concentrations of
lauric acid with a 24-h old biofilm formed by strains R20291 (C) and 630 (D) for an additional 24 h. The disruption of the preformed biofilm was quantified through
CV staining. Vehicle: 1% DMSO only. LA: lauric acid. VAN: 20 µg/mL vancomycin (40× MBC). Lauric acid MBC: 4× = 1.25 mg/mL, 2× = 0.63 mg/mL,
1× = 0.31 mg/mL, 0.5× = 0.16 mg/mL, 0.25× = 0.08 mg/mL, 0.125× = 0.04 mg/mL. Results are the mean of triplicate samples, and one-way ANOVA was
performed to assess significance. (ns, no significance; ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001).
treatment can inhibit C. difficile biofilm formation and stability
and can affect spore outgrowth.
Lauric Acid Inhibited C. difficile by
Inducing ROS Generation and Cell
Membrane Damage
To determine whether the inhibitory effect of lauric acid on
C. difficile growth is due to the disruption of cell membrane
integrity, C. difficile cells were treated with lauric acid, and the
extracellular presence of released nucleic acid was measured
(Figure 5A). In this assay, we included nisin, a broad-spectrum
polycyclic antibacterial peptide produced by Lactococcus lactis,
as a positive control, as it is known to attack bacterial cell
membranes; this leads to cytoplasmic content release and cell
lysis eventually (Ruhr and Sahl, 1985; Nobmann et al., 2010).
As expected, in the presence of the antibacterial peptide nisin, a
significant quantity of nucleic acids was detected in the culture
supernatant at 30 min after treatment. When cells were treated
with various concentrations of lauric acid, a considerably higher
quantity of nucleic acid materials was also detected compared
with the negative control, indicating that the addition of lauric
acid compromised cell membrane integrity. The viability of
C. difficile cells treated with lauric acid was further assessed
using LIVE/DEAD staining and was visualized using confocal
microscopy (Figure 5B). As lauric acid induced the rapid lysis
of C. difficile cells, as indicated in Figure 2C, to elucidate the
effects of lauric acid on C. difficile cells, these cells were treated
with sublethal concentrations of lauric acid (0.25×MBC). When
cell viability was quantified based on the percentage of cells
that stained positive for propidium iodide, treatment with lauric
acid at 0.25× MBC decreased viability to approximately 65% by
15 min after treatment (Figure 5C). By 30 min after treatment,
the viability decreased to approximately 35%. By contrast, the
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FIGURE 4 | Effect of lauric acid on C. difficile spore germination. Heat-activated spores from the C. difficile strain R20291 were incubated with 10 mM sodium
taurocholate plus 5% DMSO (positive control, PC), 5% DMSO only (negative control, NC), or various concentrations of lauric acid plus 10 mM sodium taurocholate
and 5% DMSO. Germination was monitored by measuring absorbance at 600 nm (A,B) or DPA release (C). (D) Spore outgrowth was assayed by incubating spores
in the presence of various concentrations of lauric acid for 20 min, and CFU/mL was determined by plating aliquots of spores onto BHIS agar containing TA. Results
are the mean of triplicate samples, and one-way ANOVA was performed to assess significance. (ns, no significance; ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001).
viability of the DMSO-treated control remained relatively high
(15 min: 87%, 30 min: 84%). Ultrathin-section TEM analysis
revealed that 20 min of lauric acid treatment (0.25× MBC)
was sufficient to induce substantial cell death, as indicated by
abnormal cell morphology and cytoplasmic content leakage.
These findings are similar to those of Shilling et al. (2013)
(Figure 5D and Supplementary Figure 1).
To determine whether lauric acid also induces ROS
generation, vegetative C. difficile R20291 cells were treated
with a sublethal concentration of lauric acid (0.25× and 0.5×
MBC) for up to 60 min, and intracellular ROS levels were
measured (see section “Materials and Methods”). As depicted
in Figure 6A, treatment with the antiseptic hydrogen peroxide
and tert-butyl hydroperoxide (TBHP) generated a considerable
level of ROS in a time-dependent manner. Interestingly, lauric
acid treatment also generated a substantial level of ROS over
the course of the experiment. As no molecular or biochemical
studies have been performed in C. difficile on ROS-associated
genes, from the genomic annotation, we selected four potential
antioxidant defense-associated genes. As depicted in Figure 6B,
in the presence of 0.25× MBC of lauric acid, the expression
levels of genes encoding for a putative superoxide dismutase
(locus tag CDR20291_1529) and a putative catalase (locus
tag CDR20291_1465) were upregulated (9.1- and 3.4-0 fold,
respectively, compared with untreated cells) (Figure 6B).
However, the gene expression levels of CDR20291_C0757,
which encodes for a putative superoxide reductase, and
CDR20291_1716, which encodes for a putative peroxidase, were
not significantly altered in the presence of either 0.25× or 0.5×
MBC of lauric acid. Nevertheless, the results of these experiments
suggested that the bactericidal activity of lauric acid was partly
due to the induction of membrane damage and ROS generation,
which resulted in cell lysis.
Lauric Acid Pretreatment Decreased
C. difficile-Induced Inflammation in a
Mouse Infection Model
Finally, to determine whether lauric acid affects CDI in vivo,
C57BL/6 mice were administered lauric acid orogastrically for
1 week prior to infection with purified C. difficile R20291 spores
(Supplementary Figure 2). Mice administered only PBS prior to
infection displayed symptoms of CDI, including a lack of well-
formed feces due to diarrhea and a considerable decrease in body
and cecum weight (Figures 7A–D). Gross views of the colon
and cecum indicated severe colitis (Figure 7E). By contrast, both
groups of mice that were administered either 12 mg/kg (LA-low)
or 24 mg/kg (LA-high) of lauric acid displayed healthier colon
and cecum morphology (Figure 7E), body weight recovery after
infection (Figure 7B), a substantially lower body weight decrease
(Figure 7C), and a higher cecum weight (Figure 7D) than the
PBS control group. The protective effects of lauric acid appeared
to be dose-dependent, as mice belonging to the LA-high group
appeared to exhibit less severe symptoms of CDI compared with
mice in the LA-low group. No differences were observed in the
number of heat-resistant spores recovered from fecal samples
(Figure 7F).
The expression levels of genes encoding for proinflammatory
cytokines such as tumor necrosis factor α (TNF-α), interleukin
6 (IL-6), interleukin 1β (IL-1βb), macrophage inflammatory
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FIGURE 5 | Lauric acid induces bacterial cell membrane damage. To measure the damaging effect of lauric acid on C. difficile cell membrane, the vegetative cells of
the strain R20291 were treated with various concentrations of lauric acid for up to 30 min, and cellular material leakage was quantified by measuring absorbance at
260 nm (A). Nisin served as positive control. (B) Membrane permeability was measured by incubating cells with sublethal concentrations of lauric acid (0.25× MBC)
for 15 and 30 min. Cells were then stained with SYTO9 (green) and propidium iodide (red) and imaged with confocal microscopy at 1,000× magnification. Scale
bar = 5 µM. (C) Bacterial viability was quantified by counting the number of green fluorescent and red fluorescent cells from six images. (D) TEM analysis of
vegetative cells treated with 0.25× MBC for 15 min compared with untreated control. Images were taken at 10,000× magnification, and scale bars = 0.5 µM.
Results are the mean of three independent experiments. One-way ANOVA and two-way ANOVA was performed to assess significance for (A), and (C), respectively.
ns, no significance; ∗∗∗∗P ≤ 0.0001.
FIGURE 6 | Effect of lauric acid on intracellular ROS production and ROS-related genes in C. difficile. (A) C. difficile cells were treated with lauric acid for up to
60 min, and intracellular ROS was determined by staining with the general ROS indicator CM-H2DCFDA. H2O2 and TBHP served as ROS induction control. 1%
DMSO – negative control. (B) The effect of lauric acid on ROS-related genes in C. difficile. C. difficile cells were treated with lauric acid or 1% DMSO for 30 min, and
gene expression was then measured using real-time polymerase chain reaction. CDR20291_1529 (putative superoxide dismutase), CDR20291_0757 (putative
superoxide reductase), CDR20291_1716 (putative peroxidase), and CDR20291_1465 (putative catalase). All data are presented as mean ± standard deviations, and
statistical comparisons among groups were made using one-away ANOVA (∗p ≤ 0.05, ∗∗∗∗p ≤ 0.0001). ns, not significant. All data are representative of at least
three independent experiments.
protein 2 (MIP-2), and monocyte chemoattractant protein 1
(MCP-1) were considerably decreased in the colon homogenates
of the LA-low and LA-high groups compared with those in
the PBS group (Figure 8A). In addition to gene expression,
proinflammatory cytokines and chemokines from the GAL fluid
of all three groups were analyzed. Levels of TNF-α, IL-1β, and
MCP-1 were significantly decreased in the GAL lavage fluid of
both lauric acid treatment groups compared with that in the
PBS control group (P = 0.0254, P = 0.036, and P = 0.0285,
respectively, compared with the PBS control group) (Figure 8B).
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FIGURE 7 | Lauric acid treatment protects mice from C. difficile infection. Various groups of mice receiving lauric acid or PBS only were treated with an antibiotic
cocktail and then challenged by C. difficile for 2 days. Stool consistency (A), body weight over time (B), body weight change (C), cecum weight (D), gross views of
colon and cecum (E), and heat-resistant fecal spore count 2 days post infection (F) were assessed. PBS: mice receiving PBS pre-treatment only; LA-low: mice
receiving 12 mg/kg lauric acid; LA-high: mice receiving 24 mg/kg lauric acid. All data are presented as mean ± standard deviations, and statistical comparisons
among groups were made using one-way ANOVA (n = 5, ∗∗P ≤ 0.01). ns, not significant. All data are representative of at least three independent experiments.
No statistically significant differences were observed in the levels
of IL-6 and MIP-2 detected, although the trend was similar to
that observed above. Collectively, these results demonstrated that
the administration of lauric acid could decrease the severity of
C. difficile-induced inflammation in vivo.
DISCUSSION
The main three drug resistance strategies of C. difficile are drug
inactivation, target modification, and efflux pump, which have
led to the emergence of hypervirulent drug-resistant strains
(Harnvoravongchai et al., 2017). Noticeably, in recent years, the
ability of C. difficile to tolerate multiple commonly prescribed
antibiotics, its production of potent cytotoxins (toxin A, toxin B,
and binary toxin CdtAB), and its high recurrence rate have
resulted in CDIs becoming a healthcare concern worldwide
(Martin et al., 2016). The current guideline for CDI treatment
has focused on discontinuing previous antibiotic usage, and
switching the treatment to metronidazole and vancomycin
(Ananthakrishnan, 2011). However, similar to various other
bacterial pathogens, C. difficile can develop antibiotic resistance;
therefore, alternative treatment or prevention strategies
are required. The development of new antibiotics, such as
fidaxomicin, and monoclonal antibodies, such as bezlotoxumab,
has provided clinicians with additional treatment options
(Miller, 2010; Wilcox et al., 2017), but the prescription costs of
these new medications remain high; thus, these drugs might not
be readily accessible to economically disadvantaged patients.
Furthermore, most new antibiotics are derivatives of existing
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FIGURE 8 | Decreased level of proinflammatory cytokines in C. difficile-infected mice receiving lauric acid. The level of various proinflammatory cytokines and
chemokines in colon tissues (A) and GAL (B) from mice belonging to the PBS treatment group, LA-low (12 mg/kg) group, and LA-high (24 mg/kg) group was
measured using real-time polymerase chain reactions and ELISA, respectively. All data are presented as mean ± standard deviations, and statistical comparisons
among groups were made using Student’s t-test (∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗∗P ≤ 0.0001). ns, not significant. All data are representative of at least three
independent experiments.
ones and therefore share a similar mechanism of action and
risk of drug resistance. The development of novel antibacterial
products that are less likely to result in drug resistance in bacteria
is therefore necessary. In the current study, we evaluated the
inhibitory effects of various FAs on the growth of the C. difficile
strain R20291. In our study, MCFAs, in general, were more
effective in inhibiting C. difficile growth than SCFAs and LCFAs,
with lauric acid exhibiting the lowest MBC. In contrast to the
reported effect of SCFAs on bacterial pathogens, we revealed
that SCFAs did not display considerable antibacterial activity
against C. difficile. C. difficile, similar to many other members
of the Clostridium genus, is known to produce various SCFAs
such as butyric acid; therefore, C. difficile might have developed
resistance mechanisms against these FAs (May et al., 1994;
Ferreyra et al., 2014; Pettit et al., 2014).
Lauric acid is the major component of coconut oil, an edible
oil extracted from the meat of coconuts. Lauric acid accounts for
45–53% of the overall FA composition of coconut oil; therefore,
coconut oil is a dietary supplement that can modulate serum
cholesterol levels (Katan et al., 1994; German and Dillard, 2004).
When lauric acid is ingested, it is released from its triglyceride
form and can either enter the liver through a portal vein or
can be reformed into new triglycerides and enter the lymphatic
system (Dayrit, 2015). In the serum, lauric acid is known to
oxidize rapidly; therefore, only a small amount enters the liver.
Once inside the liver, lauric acid is metabolized into acetyl-CoA
for energy production, and some reaction products can also
be transformed into ketone bodies, which also aid in energy
production. The perception that lauric acid has beneficial effects
is derived from studies that have indicated that lauric acid
consumption increased serum high density lipoprotein (HDL),
which is known to decrease the risk of coronary heart diseases
(de Roos et al., 2001; Ekanayaka et al., 2013; Eyres et al., 2016).
In addition to their ability to modulate cholesterol levels, the
antimicrobial activity of MCFAs has been established for many
years. Kabara et al. (1972) reported that compared with the
other MCFAs screened (C6–C18), lauric acid showed the most
potent effects in vitro against Gram-positive bacteria (Lynch et al.,
1983; Carpo et al., 2007). Furthermore, the 1-monoglyceride form
of lauric acid, monolaurin, exhibited an even higher potency,
although its antibacterial range was reduced. LauricidinTM,
which is composed of pure monolaurin, was patented as a
nutritional supplement. Numerous studies have since been
published on the antimicrobial activities of MCFAs against both
Gram-negative and Gram-positive pathogens, with MBC values
ranging from 0.068 to 0.375 mg/mL (Ruzin and Novick, 2000;
Bergsson et al., 2001; Hinton and Ingram, 2006; Kitahara et al.,
2006; Carpo et al., 2007; Nakatsuji et al., 2009; Fischer et al.,
2012; Theinsathid et al., 2012). Shilling et al. (2013) reported that
coconut-derived lauric acid, capric acid, and caprylic acid could
inhibit the growth of C. difficile in vitro, whereas predigested
virgin coconut oil exhibited a similar effect, although to a lesser
degree. Shilling et al. (2013) also reported that lauric acid at
250 µM (MIC) could reduce bacterial growth by 90%. Although
these previous studies have demonstrated the inhibitory effects
of lauric acid in its pure form or as a derivative of lipolyzed
virgin coconut oil, a research gap exits; none of these studies
have revealed lauric acid’s mode of action, its effect on CD
physiology, and its effects on CDIs. In our study, we extended
the antibacterial activity of lauric acid to multiple clinical isolates
that included both toxigenic and non-toxigenic strains, and we
revealed that the MBC ranged from 0.312 to 0.625 mg/mL, which
supports the results of previous studies. We noted that the IC50
values for strain 630 and R20291 were considerably different,
even though the MBC values for both strains were the same.
Several possible reasons can be provided for this discrepancy.
We used a more conservative approach for determining MBC;
that is, we used the concentration at which no any growth was
observed on agar plates. In addition, it has been reported that the
MIC values for two bacterial strains were the same, whereas their
IC50 values were considerably different (Barbour et al., 2016).
In addition to the inhibitory effect observed on vegetative cells,
lauric acid could inhibit biofilm formation. At 0.25×MBC, lauric
acid was equally as effective at reducing biofilm formation as
vancomycin applied at 20 µg/mL. This effect was probably due
to the inhibition of all cell growth. More interestingly, lauric
acid disrupted preformed biofilms, and this biofilm-damaging
effect had not been reported in other studies. Dapa et al. (2013)
reported that R20291 in vitro forms biofilms with higher mass
than strain 630 does, which corroborates our observation that the
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preformed biofilm of the strain 630 was significantly disrupted
by 1× MBC of lauric acid, in contrast with the biofilm of the
strain R20291, which required 2× MBC of lauric acid for a
disruptive effect. Future studies should investigate the effect of
lauric acid on biofilm reduction by comparing the presence of
live or dead cells in the retained biofilm. At present, the exact
mechanism underlying biofilm removal by lauric acid is unclear.
It is possible that the mild detergent effect of lauric acid not
only damages cell membranes, but also bacterial adhesins that
contribute to biofilm formation. Importantly, the biofilm removal
effect of lauric acid supports its potential use as an antibacterial
agent.
Previous studies have indicated that MCFAs, including lauric
acid, can inhibit the outgrowth of Bacillus and Clostridium
spores, although C. difficile was not included in these studies
(Ababouch et al., 1992; Shearer et al., 2000). In our study, we
also observed that lauric acid treatment was effective at reducing
spore outgrowth. Spore germination is a dynamic process that is
initiated by the hydration of the spore cortex, followed by the
release of DPA, which can be monitored by changes in OD and
by measuring the DPA level in the supernatant. In the present
study, the rate of spore germination was increased in the presence
of lauric acid, but no differences were observed in the rate of
DPA release. We hypothesize that lauric acid accelerates the rate
of germination in the presence of the germinant TA, and that
this hastens the killing of the eventually germinated vegetative
cells. Studies are currently underway to address this possibility.
Additional studies are required to determine whether lauric acid
or other MCFAs can disrupt bacterial spore coats to enhance
spore germination.
In the present study, we observed a significant increase in
membrane permeability and the release of cytoplasmic materials,
consistent with the membrane-damaging effect of lauric acid
reported in previous studies (Nobmann et al., 2010). Currently,
it is unclear how lauric acid penetrates the cell wall to reach
membrane sites. We reported almost equal nucleic acid material
release rates among nisin (positive control) and all lauric acid
treatment groups (1×–8× MBC). Furthermore, lauric acid
significantly induced ROS generation and significantly increased
the expression of genes potentially associated with oxidative
damage defense. The lower expression level of these genes in
cells treated with a high concentration of lauric acid than in cells
treated with a lower concentration of lauric acid might be due
to the rapid toxicity of lauric acid, which suppressed bacterial
metabolism. Recently, Kint et al. (2017) reported that the
alternative sigma factor σB is involved in protection against ROS.
Interestingly, although no significant differences were observed
in the expression level of CDR20291_0757 and CDR_1716 in
this study, their homologs in the strain 630 were differentially
regulated by σB. ROS regulation may be different between the
two strains, or that ROS generation induced by lauric acid in our
study might induce other genes. Future studies should conduct
a transcriptomic analysis to increase our understanding of the
extent to which lauric acid treatment affects gene expression in
C. difficile.
In our in vivo experiments, we observed that daily lauric acid
intake significantly reduced the severity of diarrhea and intestinal
inflammation associated with CDI. It is still unclear whether
the direct killing effect of lauric acid on C. difficile observed
in vitro was involved in the reduction in the inflammation
observed in vivo. Additional animal studies should focus on
increasing the sample size, a longer postinfection observation,
and determining the luminal lauric acid concentration during
infection. If the concentration of luminal lauric acid reaches
a similar level as the MIC determined in this study, then the
reduction in inflammation might be due to the direct killing of
C. difficile in the gut. It is also possible that the luminal lauric
acid concentration did not reach the MIC, which suggests that
lauric acid acted upon the host to reduce inflammation. In this
study, the observation that the number of fecal spores between
lauric acid-treated and control groups was similar indicated
an indirect effect of lauric acid in vivo. It has been reported
that MCFAs, including lauric acid, are partial PPAR-α and
PPAR-γ agonists, which are known to exert anti-inflammatory
effects (Kliewer et al., 1997; Clark, 2002; Croasdell et al.,
2015). However, more experiments are required to clarify these
outstanding questions. Collectively, the results of this study
indicate that lauric acid exhibits potent antibacterial activity
against C. difficile, and lauric acid prophylaxis may substantially
decrease the level of inflammation induced by infection with
C. difficile in vivo. The beneficial effect of lauric acid as a
food supplement or as an adjunct therapy for CDI should be
considered.
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